Independent Medical Education
The medical education activities below are non-promotional, evidenced-based, fair-balanced and can be accredited or non-accredited. The activities are developed independently by third-party providers through an educational grant from Janssen to enhance the knowledge, skills, and performance of healthcare professionals, patients, and communities.
Bladder Cancer
- Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Urothelial Bladder Cancer
- Breakfast with the Investigators: Urothelial Bladder Cancer
- Keeping It Current: Latest European Updates in Prostate and Bladder Cancer
- Oncology Today with Dr Neil Love: Special Edition — Management of Urothelial Bladder Cancer
Prostate Cancer
- Annual Meeting Genitourinary Cancer Tracks Bundle
- Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer
- Evolving Paradigm of PARP Inhibitors and Combination Therapies for mCRPC
- “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients with CRPC
- Improving the Overall Safety and Quality of Care for Your Patients with Metastatic Hormone-Sensitive Prostate Cancer: How Does Your Approach Compare with the Experts?
- Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer
- Medscape Onsite: Prostate and Bladder Cancer Updates
- Prostate Cancer Master Class: Addressing Challenges in A New Era of Personalized Care
- Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate Cancer
Non-Small Cell Lung Cancer
- AdaptiveCME: Advances in Molecular Targeted Therapies for NSCLC
- Biomarkers in NSCLC: From Detection to Novel Therapeutics and Decision-Making
- Biomarker Testing: Shaping Personalized Medicine (Episode 2)
- Can Molecular Testing Identify Which mNSCLC Patients Will Benefit From New Targeted Tx?
- Clinical Trials: How They Transform the Treatment of Cancer
- Highlights from Madrid on Perioperative Immunotherapy in Early-Stage NSCLC
- Highlights from Madrid on Targeted Therapy for Advanced NSCLC
- Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced and Early- Stage NSCLC
- Non–Small Cell Lung Cancer: Treatment Updates From the Floor of ESMO 2023
- Novel Therapeutic Approaches for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer: An Oncology Pharmacy Perspective
- Novel Therapeutics: Changing the Treatment Landscape for NSCLC (Episode 3)
- Practical Strategies for Preventing and Mitigating Toxicities of Targeted Therapy (Episode 4)
- Recorded Presentations From The NCCN 2023 Congress: Biomarkers in Solid Tumors
- The Evolution of Biomarker Testing: Revolutionizing Treatment of NSCLC (Episode 1)
- The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
- Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Non-Small Cell Lung Cancer
Lymphoma
- Highlights From Bruton’s Tyrosine Kinase Inhibitors: Updates and Advancements in the Treatment and Management of CLL/SLL
- New Pathways in the Treatment of Mantle Cell Lymphoma
- What I Tell My Patients: New Treatments and Clinical Trials —Chronic Lymphocytic Leukemia
Multiple Myeloma
- 7th Annual Live Medical Crossfire®: Hematologic Malignancies
- (2023 Specialty Pharmacy NEXT) Novel Targeted Therapies for Relapsed/Refractory Multiple Myeloma
- CCO at ASCO 2023 Symposium: Exploring the Progress and Evolving Therapeutic Paradigm in Multiple Myeloma
- Current and Emerging Treatment Strategies in Multiple Myeloma: Managed Care Considerations for Improved Patient Outcomes
- Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma
- Demystifying the Details of T-Cell-Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
- Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
- Management of CRS and ICANS with CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
- Multiple Myeloma: 2023 ASH Annual Meeting Highlights from San Diego
- Overcoming Barriers to Care in Multiple Myeloma: Recognizing the Problem and Focusing on Solutions
- Oncology Morning Commute: Emerging Data on BTCE in RRMM
- Oncology Morning Commute: Tying a T-cell to the Tumor Cell in RRMM
- Oncology Morning Commute: Using Bispecifics for the Treatment of Multiple Myeloma in Clinical Practice
- Recent Advances in BCMA-Directed Treatment in Multiple Myeloma – Insights and Application for Managed Care
- The Heterogeneity, Therapeutic Advancements, and Updated Guidelines for the Treatment of RRMM
- The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms
- Updates From the 2023 Summer Meetings: Bispecific Antibodies in Multiple Myeloma